SCHEMBL1008452

SCHEMBL1008452

CC(C)CCC[C@H](C)[C@@H]1CC[C@]2(C)[C@@H]3CC=C4C(C)(C)CC=C(O)[C@]4(C)[C@H]3CC[C@@]12C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EBP Q15125 8/20 0.47
▸ HMGCR P04035 2/20 0.40
▸ USP2 O75604 3/20 0.38
▸ LMNA P02545 2/20 0.38
▸ ABCB1 P08183 1/20 0.38
▸ OSBP P22059 1/20 0.38
▸ RORC P51449 1/20 0.38
▸ OSBP2 Q969R2 1/20 0.38
▸ CYP46A1 Q9Y6A2 1/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ NPC1L1 Q9UHC9 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ TP53 P04637 1/20 0.36
▸ FNTA P49354 1/20 0.35
▸ FNTB P49356 1/20 0.35
▸ CDC25A P30304 1/20 0.35
▸ CDC25B P30305 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL337426 1.00 EBP (0.47) EBPHMGCRUSP2LMNAABCB1
SCHEMBL337427 0.84 EBP (0.47) EBPHMGCRUSP2LMNAABCB1
SCHEMBL3229562 0.74 EBP (0.48) EBPHMGCRUSP2LMNAABCB1
SCHEMBL3229569 0.74 EBP (0.49) EBPHMGCRUSP2LMNAABCB1
SCHEMBL14864844 0.73 RORC (0.66) EBPHMGCRUSP2LMNAABCB1
SCHEMBL14602524 0.68 POLA1 (0.53) USP2LMNAABCB1OSBPRORC
SCHEMBL13391627 0.68 POLA1 (0.53) USP2LMNAABCB1OSBPRORC
SCHEMBL14641136 0.68 POLA1 (0.53) USP2LMNAABCB1OSBPRORC
SCHEMBL14976244 0.68 HMGCR (0.49) EBPHMGCR
SCHEMBL159792 0.67 EBP (0.47) EBPHMGCRCDC25ACDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020121335-A1 A PROCESS FOR PRODUCING TIRUCALLADIENOL FOR SYNTHESIS OF LIMONOIDS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2020-06-18 — — WO claimed
US-12344531-B2 Silica with ultra-fast dissolution properties SIL'INNOV SRCL (BE) 2025-07-01 — — US disclosed
US-20240059571-A1 SILICA WITH ULTRA-FAST DISSOLUTION PROPERTIES SIL'INNOV SRCL (BE) 2024-02-22 — — US disclosed
US-11427476-B2 Mesoporous silicas and method for the synthesis thereof Sil'innov S.c.r.l. (BE) 2022-08-30 — — US disclosed
EP-3939573-A1 DRUG DELIVERY SYSTEM FOR NATURAL PHENOLS CFG Pharma Srl (BE) 2022-01-19 — — EP disclosed
WO-2021069074-A1 SILICA WITH ULTRA-FAST DISSOLUTION PROPERTIES SIL'INNOV SRCL (BE) 2021-04-15 — — WO disclosed
WO-2021069108-A1 SILICA WITH ULTRA-FAST DISSOLUTION PROPERTIES SIL'INNOV SRCL (BE) 2021-04-15 — — WO disclosed
EP-3680216-A1 MESOPOROUS SILICAS AND METHOD FOR SYNTHESISING THEM Sil'Innov SCRL (BE) 2020-07-15 — — EP disclosed
WO-2020121335-A1 A PROCESS FOR PRODUCING TIRUCALLADIENOL FOR SYNTHESIS OF LIMONOIDS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2020-06-18 — — WO disclosed
WO-2020121335-A1 A PROCESS FOR PRODUCING TIRUCALLADIENOL FOR SYNTHESIS OF LIMONOIDS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2020-06-18 — — WO disclosed
EP-3445713-B1 MESOPOROUS SILICAS AND METHOD FOR THE SYNTHESIS THEREOF SILINNOV SCRL (BE) 2020-03-18 — — EP disclosed
US-20190084836-A1 Mesoporous Silicas and Method for the Synthesis Thereof Sil'innov S.c.r.l. (BE) 2019-03-21 — — US disclosed
WO-2017182245-A1 MESOPOROUS SILICAS AND METHOD FOR THE SYNTHESIS THEREOF SIL'INNOV SCRL (BE) 2017-10-26 — — WO disclosed
EP-1721983-B1 TRITERPENE HYDROXYLASE MEIJI SEIKA KAISHA (JP) 2011-01-05 — — EP disclosed
EP-2145959-A2 Triterpene Hydroxylase Meiji Seika Kaisha, Ltd. (JP) 2010-01-20 — — EP disclosed
US-7575892-B2 Expression vector encoding a triterpene hydroxylase polypeptide MEIJI SEIKA KAISHA, LTD. (JP) 2009-08-18 — — US disclosed
US-20080003639-A1 Triterpene Hydroxylase MEIJI SEIKA KAISHA, LTD. (JP) 2008-01-03 — — US disclosed
EP-1721983-A1 TRITERPENE HYDROXYLASE MEIJI SEIKA KAISHA LTD. (JP) 2006-11-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344531-B2 Silica with ultra-fast dissolution properties SI, TREH, DDOST EBP 1323/4885HMGCR 2224/4885USP2 108/4885
US-20240059571-A1 SILICA WITH ULTRA-FAST DISSOLUTION PROPERTIES SI, DDOST, TREH EBP 1405/4885HMGCR 2238/4885USP2 72/4885
US-11427476-B2 Mesoporous silicas and method for the synthesis thereof LSS, SGMS2, SGMS1 EBP 395/4885HMGCR 517/4885USP2 4043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback